Gubra specialises in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, offering research and development services to pharmaceutical and biotechnology companies on a contract basis. Founded in 2008, the company's total revenue in 2022 amounted to 199.4 million Danish crowns, with an adjusted operating profit of 19 million. ($1 = 6.9888 Danish crowns) (Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)
COPENHAGEN, March 6 (Reuters) - Danish biotech company
Gubra aims to raise 500 million Danish Crowns ($71.54 million)
through an initial public offering (IPO) and list its shares on
the Nasdaq Copenhagen exchange, the company said in a statement
on Monday.
Certain investors, including Danske Asset Management and
Danica Pension have committed to subscribe for Gubra's new
shares for a total amount of 330 million crowns.
The company intends to use the net proceeds to expand its
research activities, develop its drug candidates and technical
solutions, as well as for acquisitions, it said.
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.